Astrana is a profitable, scaled value-based care consolidator—if it executes the Prospect turnaround and reduces payer concentration, today’s discounted multiple could re-rate sharply.
Overview
Astrana Health (ASTH), formerly Apollo Medical Holdings, is a U.S. healthcare services platform built for the structural shift from fee-for-service to value-based care. It is payer-agnostic and physician-centric, aggregating independent providers into a technology-enabled network so physicians can participate in global risk contracts without building full managed-care infrastructure. As of early 2026, Astrana serves 10,000+ providers and manages ~1.1M patients across Medicare, Medicaid, and Commercial. 2024–2025 marked a major inflection via the Prospect Health acquisition, which doubled quarterly revenue to ~$956M in Q3’25 (+100% YoY) and expanded lives under management, with early standalone performance described as exceeding expectations. The company operates a three-part flywheel: Care Partners (risk-bearing, ~94% of revenue), Care Delivery (clinics/clinical access), and Care Enablement (MSO + CareOps technology). As of Jan 2026, shares trade near ~$28 with a ~$1.42B market cap and ~10x EV/EBITDA—reflecting profitability but skepticism around integration, payer concentration, and Medicare Advantage regulation—making ASTH a “show me” story trending toward “showed you” if execution continues.